Page last updated: 2024-11-13

florbetapir f 18

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

florbetapir: a PET agent for Abeta plaques; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

florbetapir F-18 : An aromatic ether consisting of a pyridine ring substituted at position 2 by a 2-{2-[2-((18)F)fluoroethoxy]ethoxy}ethoxy group and at position 5 and a 2-(4-methylaminophenyl)vinyl group. A positron emission tomography imaging ligand for the detection of amyloid aggregation associated with Alzheimer disease. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID24822371
CHEMBL ID1774461
CHEBI ID66880
SCHEMBL ID14826096
MeSH IDM0553881

Synonyms (60)

Synonym
av45 f-18
florbetapir f-18
CHEMBL1774461
florbetapir(18-f)
florbetapir f 18
florbetapir, f-18
av-45 f-18
chebi:66880 ,
florbetapir (18f)
(18f)av-45
18f-av45
18f-av-45
florbetapir f-18 (usan)
956103-76-7
amyvid (tn)
D09617
YNDIAUKFXKEXSV-CRYLGTRXSA-N
4-((1e)-2-(6-{2-(2-(2-(18f)fluoroethoxy)ethoxy)ethoxy}pyridin-3-yl)ethenyl)-n- methylbenzenamine
av-45 compound
amyvid
6w15z5r0ru ,
4-(2-(6-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-n-methylbenzamide
florbetapir (18f) [inn]
florbetapir
pet av-45
florbetapir f-18 [usan:inn]
unii-6w15z5r0ru
18fav45
benzenamine, 4-((1e)-2-(6-(2-(2-(2-(fluoro-18f)ethoxy)ethoxy)ethoxy)-3- pyridinyl)ethenyl)-n- methyl-
florbetapir (18f) [who-dd]
florbetapir f-18 [usan]
florbetapir f 18 [mi]
florbetapir ((1)f) [inn]
florbetapir f-18 [orange book]
4-((1e)-2-(6-(2-(2-(2-(18f)fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)ethenyl)-n- methylbenzenamine
florbetapir (18f) [ema epar]
4-{(e)-2-[6-(2-{2-[2-((18)f)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-n-methylaniline
gtpl7344
4-[(e)-2-[6-(2-{2-[2-(18f)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl]-n-methylaniline
SCHEMBL14826096
4-{(e)-2-[6-(2-{2-[2-(18f)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-n-methylaniline
florbetapir f18
florbetapir-fluorine-18
DB09149
[18f]florbetapir
DTXSID80241898 ,
bdbm50484946
Q5460495
18f-av45; florbetapir (18f)
4-[(e)-2-[6-[2-[2-(2-(18f)fluoranylethoxy)ethoxy]ethoxy]pyridin-3-yl]ethenyl]-n-methylaniline
benzenamine, 4-[(1e)-2-[6-[2-[2-[2-(fluoro-18f)ethoxy]ethoxy]ethoxy]-3-pyridinyl]ethenyl]-n-methyl-
AKOS040751811
v09ax05
4-((1e)-2-(6-(2-(2-(2-(18f)fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)ethenyl)-n-methylbenzenamine
florbetapirum (18f)
4-((e)-2-(6-(2-(2-(2-(18f)fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)ethenyl)-n-methylaniline
4-((e)-2-(6-(2-(2-(2-((18)f)fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)ethenyl)-n-methylaniline
(18f)florbetapir
dtxcid10164389
benzenamine, 4-((1e)-2-(6-(2-(2-(2-(fluoro-18f)ethoxy)ethoxy)ethoxy)-3-pyridinyl)ethenyl)-n-methyl-

Research Excerpts

Overview

Florbetapir F 18 (F-AV-45) is a positron emission tomography imaging ligand for the detection of amyloid aggregation associated with Alzheimer disease.

ExcerptReferenceRelevance
"Florbetapir F 18 (F-AV-45) is a positron emission tomography imaging ligand for the detection of amyloid aggregation associated with Alzheimer disease. "( Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.
Beach, TG; Bedell, BJ; Bennett, DA; Choi, SR; Clark, CM; Hefti, F; Krautkramer, MJ; Kung, HF; Schneider, JA; Skovronsky, DM; Zehntner, SP,
)
1.85

Toxicity

ExcerptReferenceRelevance
" Safety was assessed by monitoring adverse events, vital signs, clinical laboratory assessments, and electrocardiograms."( Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
Agbulos, A; Breault, C; Iwata, A; Joshi, AD; Lu, M; Momose, T; Namiki, C; Okubo, Y; Pontecorvo, MJ; Senda, M; Takita, Y, 2015
)
0.42
" A total of 6 subjects (5 of whom were in the CN group) had at least 1 treatment-emergent adverse event (TEAE)."( Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
Agbulos, A; Breault, C; Iwata, A; Joshi, AD; Lu, M; Momose, T; Namiki, C; Okubo, Y; Pontecorvo, MJ; Senda, M; Takita, Y, 2015
)
0.42
" Florbetapir ((18)F) was safe and well tolerated."( Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
Agbulos, A; Breault, C; Iwata, A; Joshi, AD; Lu, M; Momose, T; Namiki, C; Okubo, Y; Pontecorvo, MJ; Senda, M; Takita, Y, 2015
)
0.42
"Regarding the safety evaluation, failure of device and adverse events were recorded."( [Safety and Effectiveness of NEPTIS Plug-01 and Florbetapir (
Matsumura, T; Nakamura, T; Senda, M; Yamamoto, Y, 2019
)
0.51
" No adverse event was reported from those 12 patients."( [Safety and Effectiveness of NEPTIS Plug-01 and Florbetapir (
Matsumura, T; Nakamura, T; Senda, M; Yamamoto, Y, 2019
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
" The validated method was successfully applied to a pharmacokinetic study of AV-45 in rats."( Study the pharmacokinetics of AV-45 in rat plasma and metabolism in liver microsomes by ultra-performance liquid chromatography with mass spectrometry.
Qiao, J; Yin, W; Zhou, X; Zhu, L, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" Using both beta-amyloid burden and age as continuous predictors of encoding activity, we report a dose-response relationship of beta-amyloid load to neural function, beyond the effects of age."( Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan.
Bischof, GN; Devous, MD; Hebrank, AC; Kennedy, KM; Park, DC; Rodrigue, KM, 2012
)
0.38
"Using bootstrap resampling of list-mode data from 18F-florbetapir scans, a total of 800 images were reconstructed for four different dosage levels: 100, 50, 20, and 10%."( The effect of 18F-florbetapir dose reduction on region-based classification of cortical amyloid deposition.
Anton-Rodriguez, J; Evans, R; Herholz, K; Hinz, R; Matthews, JC, 2014
)
0.4
"To examine whether a continuous, dose-response relationship between amyloid burden and cognitive decline was present among middle-aged and older adults."( Association of Longitudinal Cognitive Decline With Amyloid Burden in Middle-aged and Older Adults: Evidence for a Dose-Response Relationship.
Bischof, GN; Chen, X; Devous, MD; Farrell, ME; Festini, SB; Kennedy, KM; Park, DC; Rieck, JR; Rodrigue, KM; Wig, G, 2017
)
0.46
" The greater dosage of rs3807779 SNP increased the detrimental effect of Aβ deposition on cortical thickness."( Polymorphism in the MAGI2 Gene Modifies the Effect of Amyloid β on Neurodegeneration.
Choi, JK; Jeong, Y; Kim, HR; Lee, T,
)
0.13
"Six cohorts were dosed with donanemab: single dose 10-, 20- or 40- mg/kg (N = 18), multiple doses of 10-mg/kg every 2 weeks for 24 weeks (N = 10), and 10- or 20-mg/kg every 4 weeks for 72 weeks (N=18) or placebo (N = 15)."( Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
Aguiar, G; Ardayfio, P; Cheng, YJ; Chua, L; Dage, JL; Duggan Evans, C; Fleisher, AS; Gueorguieva, I; Ishibai, M; Lo, AC; Lowe, SL; Mullins, G; Shcherbinin, S; Sims, JR; Takaichi, G; Willis, BA, 2021
)
0.62
" Repeated dosing resulted in continued florbetapir positron emission tomography reductions over time compared to single dosing with 6 out of 28 patients attaining complete amyloid clearance within 24 weeks."( Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
Aguiar, G; Ardayfio, P; Cheng, YJ; Chua, L; Dage, JL; Duggan Evans, C; Fleisher, AS; Gueorguieva, I; Ishibai, M; Lo, AC; Lowe, SL; Mullins, G; Shcherbinin, S; Sims, JR; Takaichi, G; Willis, BA, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
radioactive imaging agentnull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
(18)F radiopharmaceutical
substituted aniline
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amyloid-beta precursor proteinHomo sapiens (human)Ki0.00290.00010.08560.8900AID445593; AID673978; AID695046
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (79)

Processvia Protein(s)Taxonomy
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
cognitionAmyloid-beta precursor proteinHomo sapiens (human)
G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglial cell activationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
suckling behaviorAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activation involved in immune responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of translationAmyloid-beta precursor proteinHomo sapiens (human)
protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
intracellular copper ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
endocytosisAmyloid-beta precursor proteinHomo sapiens (human)
response to oxidative stressAmyloid-beta precursor proteinHomo sapiens (human)
cell adhesionAmyloid-beta precursor proteinHomo sapiens (human)
regulation of epidermal growth factor-activated receptor activityAmyloid-beta precursor proteinHomo sapiens (human)
Notch signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
axonogenesisAmyloid-beta precursor proteinHomo sapiens (human)
learning or memoryAmyloid-beta precursor proteinHomo sapiens (human)
learningAmyloid-beta precursor proteinHomo sapiens (human)
mating behaviorAmyloid-beta precursor proteinHomo sapiens (human)
locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
axo-dendritic transportAmyloid-beta precursor proteinHomo sapiens (human)
cholesterol metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of cell population proliferationAmyloid-beta precursor proteinHomo sapiens (human)
adult locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
visual learningAmyloid-beta precursor proteinHomo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglia developmentAmyloid-beta precursor proteinHomo sapiens (human)
axon midline choice point recognitionAmyloid-beta precursor proteinHomo sapiens (human)
neuron remodelingAmyloid-beta precursor proteinHomo sapiens (human)
dendrite developmentAmyloid-beta precursor proteinHomo sapiens (human)
regulation of Wnt signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
extracellular matrix organizationAmyloid-beta precursor proteinHomo sapiens (human)
forebrain developmentAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection developmentAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of chemokine productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-1 beta productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-6 productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of tumor necrosis factor productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of multicellular organism growthAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of neuron differentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of glycolytic processAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of JNK cascadeAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAmyloid-beta precursor proteinHomo sapiens (human)
collateral sprouting in absence of injuryAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of inflammatory responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of synapse structure or activityAmyloid-beta precursor proteinHomo sapiens (human)
synapse organizationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of calcium-mediated signalingAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular process controlling balanceAmyloid-beta precursor proteinHomo sapiens (human)
synaptic assembly at neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
neuron apoptotic processAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
neuron cellular homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAmyloid-beta precursor proteinHomo sapiens (human)
response to interleukin-1Amyloid-beta precursor proteinHomo sapiens (human)
modulation of excitatory postsynaptic potentialAmyloid-beta precursor proteinHomo sapiens (human)
NMDA selective glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of spontaneous synaptic transmissionAmyloid-beta precursor proteinHomo sapiens (human)
cytosolic mRNA polyadenylationAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionAmyloid-beta precursor proteinHomo sapiens (human)
cellular response to amyloid-betaAmyloid-beta precursor proteinHomo sapiens (human)
regulation of presynapse assemblyAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection maintenanceAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of T cell migrationAmyloid-beta precursor proteinHomo sapiens (human)
central nervous system developmentAmyloid-beta precursor proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
serine-type endopeptidase inhibitor activityAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
heparin bindingAmyloid-beta precursor proteinHomo sapiens (human)
enzyme bindingAmyloid-beta precursor proteinHomo sapiens (human)
identical protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
transition metal ion bindingAmyloid-beta precursor proteinHomo sapiens (human)
receptor ligand activityAmyloid-beta precursor proteinHomo sapiens (human)
PTB domain bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein serine/threonine kinase bindingAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor activator activityAmyloid-beta precursor proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (41)

Processvia Protein(s)Taxonomy
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
dendriteAmyloid-beta precursor proteinHomo sapiens (human)
extracellular regionAmyloid-beta precursor proteinHomo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
nuclear envelope lumenAmyloid-beta precursor proteinHomo sapiens (human)
cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
mitochondrial inner membraneAmyloid-beta precursor proteinHomo sapiens (human)
endosomeAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulum lumenAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
Golgi lumenAmyloid-beta precursor proteinHomo sapiens (human)
Golgi-associated vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cytosolAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
clathrin-coated pitAmyloid-beta precursor proteinHomo sapiens (human)
cell-cell junctionAmyloid-beta precursor proteinHomo sapiens (human)
synaptic vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
membraneAmyloid-beta precursor proteinHomo sapiens (human)
COPII-coated ER to Golgi transport vesicleAmyloid-beta precursor proteinHomo sapiens (human)
axonAmyloid-beta precursor proteinHomo sapiens (human)
growth coneAmyloid-beta precursor proteinHomo sapiens (human)
platelet alpha granule lumenAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
endosome lumenAmyloid-beta precursor proteinHomo sapiens (human)
trans-Golgi network membraneAmyloid-beta precursor proteinHomo sapiens (human)
ciliary rootletAmyloid-beta precursor proteinHomo sapiens (human)
dendritic spineAmyloid-beta precursor proteinHomo sapiens (human)
dendritic shaftAmyloid-beta precursor proteinHomo sapiens (human)
perikaryonAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
apical part of cellAmyloid-beta precursor proteinHomo sapiens (human)
synapseAmyloid-beta precursor proteinHomo sapiens (human)
perinuclear region of cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
presynaptic active zoneAmyloid-beta precursor proteinHomo sapiens (human)
spindle midzoneAmyloid-beta precursor proteinHomo sapiens (human)
recycling endosomeAmyloid-beta precursor proteinHomo sapiens (human)
extracellular exosomeAmyloid-beta precursor proteinHomo sapiens (human)
receptor complexAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID668943Biodistribution in ICR mouse liver at 925 KBq, iv after 30 mins by gamma counting2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID708330Drug uptake in ddY mouse brain at 370 kBq/100 ul, iv at 60 mins by gamma-counting analysis2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Novel ¹⁸F-labeled benzoxazole derivatives as potential positron emission tomography probes for imaging of cerebral β-amyloid plaques in Alzheimer's disease.
AID656735Binding affinity to amyloid beta aggregates in postmortem human Alzheimer's disease brain homogenates after 2 hrs by gamma counting2011ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9
A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques.
AID596273Ratio of drug level in brain after 2 mins to brain after 60 mins in ddY mouse heart at 185 to 370 kBq, iv2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Novel 18F-labeled benzofuran derivatives with improved properties for positron emission tomography (PET) imaging of β-amyloid plaques in Alzheimer's brains.
AID668930Binding affinity to amyloid-beta plaque in cerebral blood vessels of normal human cerebral amyloid angiopathy region of brain after 1 hr2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID760070Ratio of drug uptake in Tg2576 ddY mouse brain at 23.4 to 48.2 kBq, iv measured at 2 mins to drug uptake in Tg2576 ddY transgenic mouse brain at 23.4 to 48.2 kBq, iv measured at 60 mins2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
Structure-Activity Relationships and in Vivo Evaluation of Quinoxaline Derivatives for PET Imaging of β-Amyloid Plaques.
AID695088Partition coefficient, log P of the compound2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Synthesis and evaluation of ¹⁸F-labeled styryltriazole and resveratrol derivatives for β-amyloid plaque imaging.
AID695045Drug uptake in mouse brain after 2 mins2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Synthesis and evaluation of ¹⁸F-labeled styryltriazole and resveratrol derivatives for β-amyloid plaque imaging.
AID708094Ratio of drug uptake in brain at 2 mins to drug uptake in brain at 60 mins in CD1 mouse at 10 uCi, iv2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Novel ¹⁸F-labeled benzoxazole derivatives as potential positron emission tomography probes for imaging of cerebral β-amyloid plaques in Alzheimer's disease.
AID708095Drug uptake in CD1 mouse brain at 10 uCi, iv at 2 mins by gamma-counting analysis2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Novel ¹⁸F-labeled benzoxazole derivatives as potential positron emission tomography probes for imaging of cerebral β-amyloid plaques in Alzheimer's disease.
AID668939Biodistribution in ICR mouse bone at 925 KBq, iv after 2 mins by gamma counting2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID668934Biodistribution in ICR mouse blood at 925 KBq, iv after 2 mins by gamma counting2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID668927Displacement of [18F]-amyvid from amyloid-beta aggregates in alzheimer's disease patient brain homogenates after 1 hr2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID668941Biodistribution in ICR mouse muscle at 925 KBq, iv after 30 mins by gamma counting2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID1273352Ratio of drug level in CD1 mouse brain at 370 kBq measured at 2 to 60 mins2015European journal of medicinal chemistry, Nov-02, Volume: 104Preliminary evaluation of fluoro-pegylated benzyloxybenzenes for quantification of β-amyloid plaques by positron emission tomography.
AID1273351Biodistribution in CD1 mouse brain at 370 kBq measured at 2 mins by gamma counting analysis2015European journal of medicinal chemistry, Nov-02, Volume: 104Preliminary evaluation of fluoro-pegylated benzyloxybenzenes for quantification of β-amyloid plaques by positron emission tomography.
AID668931Binding affinity to amyloid-beta plaque in parenchymal region of normal human brain after 1 hr2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID684731Biodistribution in ICR mouse brain at 370 kBq, iv after 2 mins by gamma counting2012European journal of medicinal chemistry, Nov, Volume: 57¹⁸F-labeled 2-phenylquinoxaline derivatives as potential positron emission tomography probes for in vivo imaging of β-amyloid plaques.
AID706000Displacement of [125I]-IMPY from amyloid beta (1 to 42) fibrils after 2 hrs by gamma-counting analysis2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Synthesis and evaluation of novel ¹⁸F labeled 2-pyridinylbenzoxazole and 2-pyridinylbenzothiazole derivatives as ligands for positron emission tomography (PET) imaging of β-amyloid plaques.
AID668945Biodistribution in ICR mouse bone at 925 KBq, iv after 30 mins by gamma counting2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID668940Biodistribution in ICR mouse blood at 925 KBq, iv after 30 mins by gamma counting2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID668936Biodistribution in ICR mouse kidney at 925 KBq, iv after 2 mins by gamma counting2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID656737Drug uptake in CD-1 mouse brain after 60 mins2011ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9
A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques.
AID708097Ratio of drug uptake in brain at 2 mins to drug uptake in brain at 60 mins in ddY mouse at 370 kBq/100 ul, iv2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Novel ¹⁸F-labeled benzoxazole derivatives as potential positron emission tomography probes for imaging of cerebral β-amyloid plaques in Alzheimer's disease.
AID708318Displacement of [125I]IMPY from amyloid beta (1 to 42) fibrils after 2 hrs by gamma-counting analysis2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Novel ¹⁸F-labeled benzoxazole derivatives as potential positron emission tomography probes for imaging of cerebral β-amyloid plaques in Alzheimer's disease.
AID623031Drug uptake in mouse brain2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Synthesis and evaluation of 1-(4-[¹⁸F]fluoroethyl)-7-(4'-methyl)curcumin with improved brain permeability for β-amyloid plaque imaging.
AID684725Displacement of [125I]IMPY from amyloid beta (1 to 42) after 2 hrs by gamma counting2012European journal of medicinal chemistry, Nov, Volume: 57¹⁸F-labeled 2-phenylquinoxaline derivatives as potential positron emission tomography probes for in vivo imaging of β-amyloid plaques.
AID668942Biodistribution in ICR mouse kidney at 925 KBq, iv after 30 mins by gamma counting2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID760071Biodistribution in Tg2576 ddY mouse brain at 23.4 to 48.2 kBq, iv measured at 2 to 10 mins by autoradiography2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
Structure-Activity Relationships and in Vivo Evaluation of Quinoxaline Derivatives for PET Imaging of β-Amyloid Plaques.
AID695043Binding affinity to amyloid beta (1-42) aggregates2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Synthesis and evaluation of ¹⁸F-labeled styryltriazole and resveratrol derivatives for β-amyloid plaque imaging.
AID656736Drug uptake in CD-1 mouse brain after 2 mins2011ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9
A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques.
AID684724Binding affinity to beta-amyloid2012European journal of medicinal chemistry, Nov, Volume: 57¹⁸F-labeled 2-phenylquinoxaline derivatives as potential positron emission tomography probes for in vivo imaging of β-amyloid plaques.
AID684726Lipophilicity, log D of the compound2012European journal of medicinal chemistry, Nov, Volume: 57¹⁸F-labeled 2-phenylquinoxaline derivatives as potential positron emission tomography probes for in vivo imaging of β-amyloid plaques.
AID755102Displacement of [125I]IMPY from amyloid beta in brain homogenate of Alzheimer's disease patient after 2 hrs by gamma counting analysis2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Synthesis and biological evaluation of 18F-labled 2-phenylindole derivatives as PET imaging probes for β-amyloid plaques.
AID708332Drug uptake in ddY mouse brain at 370 kBq/100 ul, iv at 2 mins by gamma-counting analysis2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Novel ¹⁸F-labeled benzoxazole derivatives as potential positron emission tomography probes for imaging of cerebral β-amyloid plaques in Alzheimer's disease.
AID705777Drug uptake in CD1 mouse brain at 60 mins at 10 uCi, iv2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Synthesis and evaluation of novel ¹⁸F labeled 2-pyridinylbenzoxazole and 2-pyridinylbenzothiazole derivatives as ligands for positron emission tomography (PET) imaging of β-amyloid plaques.
AID668929Binding affinity to amyloid-beta plaque in parenchymal region of alzheimer's disease patient brain after 1 hr2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID708096n-Octanol-PBS buffer partition coefficient, log D of the compound at 370 kBq after 3 mins at pH 7.42012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Novel ¹⁸F-labeled benzoxazole derivatives as potential positron emission tomography probes for imaging of cerebral β-amyloid plaques in Alzheimer's disease.
AID668944Biodistribution in ICR mouse brain at 925 KBq, iv after 30 mins by gamma counting2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID695046Binding affinity to amyloid beta (1-42) aggregates in human Alzheimer's disease brain sections2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Synthesis and evaluation of ¹⁸F-labeled styryltriazole and resveratrol derivatives for β-amyloid plaque imaging.
AID668935Biodistribution in ICR mouse muscle at 925 KBq, iv after 2 mins by gamma counting2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID695086Ratio of drug uptake in mouse brain after 2 mins to 60 mins2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Synthesis and evaluation of ¹⁸F-labeled styryltriazole and resveratrol derivatives for β-amyloid plaque imaging.
AID668938Biodistribution in ICR mouse brain at 925 KBq, iv after 2 mins by gamma counting2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID673978Binding affinity to human amyloid beta plaque2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing.
AID668928Binding affinity to amyloid-beta plaque in cerebral blood vessels of alzheimer's disease patient cerebral amyloid angiopathy region of brain after 1 hr2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID668937Biodistribution in ICR mouse liver at 925 KBq, iv after 2 mins by gamma counting2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID445593Binding affinity to Beta amyloid aggregates in Alzheimer's disease patient brain by competitive binding assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.
AID705779Drug uptake in CD1 mouse brain at 2 mins at 10 uCi, iv2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Synthesis and evaluation of novel ¹⁸F labeled 2-pyridinylbenzoxazole and 2-pyridinylbenzothiazole derivatives as ligands for positron emission tomography (PET) imaging of β-amyloid plaques.
AID683091Ratio of drug level in ICR mouse brain after 2 mins to ICR mouse brain after 60 mins at 370 kBq, iv2012European journal of medicinal chemistry, Nov, Volume: 57¹⁸F-labeled 2-phenylquinoxaline derivatives as potential positron emission tomography probes for in vivo imaging of β-amyloid plaques.
AID705790Ratio of drug uptake in brain at 2 mins to drug uptake in brain at 60 mins in CD1 mouse at 10 uCi, iv2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Synthesis and evaluation of novel ¹⁸F labeled 2-pyridinylbenzoxazole and 2-pyridinylbenzothiazole derivatives as ligands for positron emission tomography (PET) imaging of β-amyloid plaques.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (349)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (0.29)29.6817
2010's279 (79.94)24.3611
2020's69 (19.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.16 (24.57)
Research Supply Index5.97 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index37.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials24 (6.58%)5.53%
Reviews18 (4.93%)6.00%
Case Studies22 (6.03%)4.05%
Observational4 (1.10%)0.25%
Other297 (81.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]